Citations

Showing 10 of 108094 citations.

Amyloid‐Related Imaging Abnormalities in the DIAN‐TU‐001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease
Joseph‐Mathurin, Nelly , Li, Yan , McCullough, Austin , Hofmann, Carsten, Wojtowicz, Jakub , Park, Ethan, Wang, Guoqiao , Preboske, Gregory M., Gordon, Brian A. , Chen, Charles D., Flores, Shaney , Aggarwal, Neelum T. , Berman, Sarah , Bird, Thomas D., Borowski, Bret, Chhatwal, Jasmeer P. , Clarnette, Roger, Fagan, Anne M. , Farlow, Martin R. , Fox, Nick C. , Gauthier, Serge , Hassenstab, Jason , Hobbs, Diana A. , Holdridge, Karen C. , Hornbeck, Russ C. , Jiménez‐Velázquez, Ivonne Z. , Klein, Gregory , Xiong, Chengjie , Mancini, Michele , McKay, Nicole S. , Mummery, Catherine J. , Ringman, John M. , Snider, B. Joy, Suzuki, Kazushi , Yaari, R. , Perrin, Richard J. , Bateman, Randall J. , Salloway, Stephen , Clifford, David B., Unit, For the Dominantly Inherited Alzheimer Network Trials, Wang, Qing , Gordon, Brian A , Chen, Charles D , Jucker, Mathias , Ringman, John M , Salloway, Steve , Benzinger, Tammie L S , Bateman, Randall J , Joseph-Mathurin, Nelly , Xiong, Chengjie , Fox, Nick C , Hassenstab, Jason , Berman, Sarah , Llibre‐Guerra, Jorge J. , Li, Yan, Wáng, Qīng , Black, Sandra E. , Brooks, William S. , Cruchaga, Carlos , Honig, Lawrence S. , Hsiung, Ging‐Yuek Robin , Jack, Clifford R. , Masellis, Mario , Shimada, Hiroyuki , Wallon, David , Xiong, Chengjie , McDade, Eric , Benzinger, Tammie L.S. , Unit, For the Dominantly Inherited Alzheimer Network Trials

Mayo Clinic

Annals of Neurology | September 24, 2022 | Volume: 92 | Issue: 5 | Pages: 729-744

10.1002/ana.26511 | PMID 36151869 Get It

ObjectiveTo determine the characteristics of participants with amyloid‐related imaging abnormalities (ARIA) in a trial of gantenerumab or solanezumab in dominantly inherited Alzheimer disease (DIAD).Methods142 DIAD mutation carriers received either gantenerumab SC (n = 52), solanezumab IV (n = 50), or placebo (n = 40). Participants underwent assessments with the Clinical Dementia Rating® (CDR®), neuropsychological testing, CSF biomarkers, β‐amyloid positron emission tomography (PET), and magnetic resonance imaging (MRI) to monitor ARIA. Cross‐sectional and longitudinal analyses evaluated potential ARIA‐related risk factors.ResultsEleven participants developed ARIA‐E, including 3 with mild symptoms. No ARIA‐E was reported under solanezumab while gantenerumab was associated with ARIA‐E compared to placebo (odds ratio [OR] = 9.1, confidence interval [CI][1.2, 412.3]; p = 0.021). Under gantenerumab, APOE‐ɛ4 carriers were more likely to develop ARIA‐E (OR = 5.0, CI[1.0, 30.4]; p = 0.055), as were individuals with microhemorrhage at baseline (OR = 13.7, CI[1.2, 163.2]; p = 0.039). No ARIA‐E was observed at the initial 225 mg/month gantenerumab dose, and most cases were observed at doses >675 mg. At first ARIA‐E occurrence, all ARIA‐E participants were amyloid‐PET+, 60% were CDR >0, 60% were past their estimated year to symptom onset, and 60% had also incident ARIA‐H. Most ARIA‐E radiologically resolved after dose adjustment and developing ARIA‐E did not significantly increase odds of trial discontinuation. ARIA‐E was more frequently observed in the occipital lobe (90%). ARIA‐E severity was associated with age at time of ARIA‐E.InterpretationIn DIAD, solanezumab was not associated with ARIA. Gantenerumab dose over 225 mg increased ARIA‐E risk, with additional risk for individuals APOE‐ɛ4(+) or with microhemorrhage. ARIA‐E was reversible on MRI in most cases, generally asymptomatic, without additional risk for trial discontinuation. ANN NEUROL 2022;92:729–744
Larynx proteomics after jellyfish collagen IL: Increased ECM/collagen and suppressed inflammation
Bowen, Andrew J. , Ekbom, Dale C. , Hunter, Danielle E., Voss, Stephen G. , Mearns‐Spragg, Andrew , Oldenburg, Michael , San‐Marina, Serban , Hunter, Danielle, Voss, Stephen , Oldenburg, Michael S , San-Marina, Serban , Bowen, Andrew Jay , Bartemes, Kathleen R.

Mayo Clinic

Laryngoscope Investigative Otolaryngology | September 24, 2022 | Volume: 7 | Issue: 5 | Pages: 1513-1520

10.1002/lio2.924 | PMID 36258863 Get It

AbstractObjectives/HypothesisCompare proteomic profiles of rabbit vocal folds (VFs) injected with micronized cross‐linked jellyfish collagen “collagen Type 0” (MX‐JC) against two clinical products for injection medialization laryngoplasty (IL).Study DesignAnimal model.MethodsLeft recurrent laryngeal nerve sectioning and IL were performed in New Zealand White rabbits (N = 6/group). Group 1 received (MX‐JC) and adipose‐derived stem cells (ADSCs), Group 2, MX‐JC alone; Group 3, cross‐linked hyaluronic acid; and Group 4, micronized acellular dermis. Animals were sacrificed at 4 and 12 weeks. Proteomic profiling of injected versus noninjected VFs by nano‐liquid chromatography, tandem mass spectrometry, and reactome gene ontology analysis was performed.ResultsOverall, 37–61 proteins were found to be upregulated and 60–284 downregulated in injected versus non‐injected VFs (>1.5 fold, false discovery rate‐adjusted p < .05). Over‐representation analysis (% of total) revealed top up‐regulated pathways at 4 and 12 weeks, respectively: Group 1, keratan sulfate metabolism (46%) and cellular processes (29%); Group 2, extracellular matrix (ECM)/collagen processes (33%) and beta oxidation (39%); Group 3, cellular processes (50%) and energy metabolism (100%); and Group 4, keratan sulfate metabolism (31%) and inflammation (50%). Top downregulated pathways were: Group 1, Inflammation (36%) and glucose/citric acid metabolism (42%); Group 2, cell signaling (38%) and glucose/citric acid metabolism (35%); Group 3, keratan sulfate metabolism (31%) and ECM/collagen processes (48%); and Group 4, glucose/citric acid metabolism (33%) and ECM/collagen processes (43%).ConclusionsMX‐JC “collagen Type 0” upregulates pathways related to ECM/collagen formation and downregulates pathways related to inflammation suggesting that it is promising biomaterial for IL.Level of EvidenceNA
Duration of frontline therapy and impact on clinical outcomes in newly diagnosed multiple myeloma patients not receiving frontline stem cell transplant
Ailawadhi, Sikander , Ogbonnaya, Augustina , Murty, Sharanya, Cherepanov, Dasha , Schroader, Bridgette Kanz , Romanus, Dorothy , Farrelly, Eileen, Chari, Ajai , Ailawadhi, Sikander , Chari, Ajai

Mayo Clinic

Cancer Medicine | September 24, 2022 | Volume: 12 | Issue: 3 | Pages: 3145-3159

10.1002/cam4.5239 | PMID 36151787 Get It

AbstractBackgroundExtended first‐line therapy (1LT) has improved clinical outcomes in newly diagnosed multiple myeloma (NDMM). This retrospective study of NDMM patients evaluated the relationship between dose‐attenuation of 1LT and duration of therapy (DOT) and DOT on outcomes.MethodsAdults with NDMM not undergoing stem cell transplant (SCT) from January 1, 2012 toMarch 31, 2018 from the Integrated Oncology Network were included; 300 were randomly selected for chart review. 1LT DOT, time to next treatment (TTNT), progression‐free survival (PFS), and overall survival (OS) were estimated using Kaplan–Meier analysis. Marginal structural models evaluated relationships between DOT and TTNT, PFS, and OS at 2 years accounting for confounders and survival bias from the time‐dependent nature of DOT.ResultsOf 300 chart‐reviewed patients, 93 were excluded for incomplete data or meeting exclusion criteria. Among 207 NDMM patients, median age was 74 years; 146 (70.5%) did not receive dose‐attenuation during 1LT. Patients with short DOT were older, frailer, with a higher comorbidity burden, and a significantly lower proportion had an Eastern Cooperative Oncology Group PS = 0. As DOT increased, more patients underwent dose‐attenuation (p < 0.0001). The median 1LT DOT was 20.9 (95% confidence interval [CI]: 13.9, 26.4) versus 4.2 months (95% CI: 3.2, 4.9) for patients receiving versus not receiving dose‐attenuation, respectively (p < 0.0001). After accounting for survival bias, confounder‐adjusted TTNT was prolonged with each additional month of 1LT (odds ratio [OR]: 0.76 [95% CI: 0.75, 0.78]); likelihoods of risks of disease progression (OR: 0.87 [95% CI: 0.86, 0.88]) and death at 2 years (OR: 0.72 [95% CI: 0.70, 0.74]) were reduced with each month of 1LT (p < 0.0001 for all outcomes).ConclusionsDose‐attenuated 1LT was associated with longer DOT among patients with non‐SCT NDMM. Each additional month of 1LT was associated with a reduced adjusted likelihood of disease progression and death at 2 years. Dose‐attenuation of 1LT can extend DOT; longer DOT may improve clinical outcomes.
COVID Symptoms, Symptom Clusters, and Predictors for Becoming a Long-Hauler Looking for Clarity in the Haze of the Pandemic
Pinto, Melissa D. , Abrahim, Heather L. , Lambert, Natalie , Nurmi, Erika L. , Chakraborty, Rana , Pinto, Melissa D , Downs, Charles A , Huang, Yong, Borelli, Jessica L. , Mehrabadi, Milad Asgari , Dutt, Nikil D. , Rahmani, Amir M.

Mayo Clinic

Clinical Nursing Research | September 24, 2022 | Volume: 31 | Issue: 8 | Pages: 1390-1398

10.1177/10547738221125632 | PMID 36154716 Get It

Post-acute sequelae of SARS-CoV-2 (PASC) is defined as persistent symptoms after apparent recovery from acute COVID-19 infection, also known as COVID-19 long-haul. We performed a retrospective review of electronic health records (EHR) from the University of California COvid Research Data Set (UC CORDS), a de-identified EHR of PCR-confirmed SARS-CoV-2-positive patients in California. The purposes were to (1) describe the prevalence of PASC, (2) describe COVID-19 symptoms and symptom clusters, and (3) identify risk factors for PASC. Data were subjected to non-negative matrix factorization to identify symptom clusters, and a predictive model of PASC was developed. PASC prevalence was 11% (277/2,153), and of these patients, 66% (183/277) were considered asymptomatic at days 0–30. Five PASC symptom clusters emerged and specific symptoms at days 0–30 were associated with PASC. Women were more likely than men to develop PASC, with all age groups and ethnicities represented. PASC is a public health priority.
The ASA Classification System as a Predictive Factor to Stay at the Virtual Hybrid Care Hotel
Ávila, Francisco R. , Maita, Karla C. , Garcia, John P. , Forte, Antonio J. , Matcha, Gautam , Pagán, Ricardo J. , Maniaci, Michael J. , Paulson, Margaret R. , Avila, Francisco R , Torres-Guzman, Ricardo A, Garcia, John P , Forte, Antonio Jorge , Matcha, Gautam V, Maniaci, Michael J , Chadha, Ryan , Torres‐Guzman, Ricardo A.

Mayo Clinic

The American Surgeon™ | September 24, 2022 | Volume: 89 | Issue: 11 | Pages: 4707-4714

10.1177/00031348221129524 | PMID 36154300 Get It

Introduction The Care Hotel is a virtual hybrid care model for postoperative patients after low-risk procedures which allow recovery in an outpatient environment. This study aimed to analyze if the American Society of Anesthesiologists Physical Status (ASA PS) Classification System can be used as a predictive factor for staying at Mayo Clinic’s Care Hotel. Methods This retrospective cohort study was conducted between July 23, 2020, and June 4, 2021, at Mayo Clinic in Florida, a 306-bed community academic hospital. ASA PS Class and post-procedure care setting (Care Hotel vs inpatient ward) were collected. Patients were classified into two ASA PS groups (ASA PS Classes 1-2 and 3-4). Pearson’s Chi-square test was used to determine if the ASA PS Class and having stayed or not at the Care Hotel were independent and an Odds Ratio (OR) calculated. Results Out of 392 surgical and procedural patients, 272 (69.39%) chose the Care Hotel and 120 (30.61%) chose the inpatient ward. There was a statistically significant association between ASA PS Class and staying at the Care Hotel, P < .01. The OR of preferring to stay at the Care Hotel in patients with ASA PS Class 1-2 vs ASA PC Class 3-4 was 1.91 ( P = .0041, 95% CI: 1.229-2.982) Conclusion Patients with ASA PS Classes 1-2 are almost twice as likely to elect to stay at the Care Hotel compared to those with ASA PS Classes 3-4. This finding may help care teams focus their Care hotel recruitment efforts.
Perioperative management of myeloproliferative neoplasms: A pan‐Canadian physician survey and international expert opinion
Szuber, Natasha , Toliopoulos, Panagiota , Busque, Lambert , Cerquozzi, Sonia , Foltz, Lynda, Gupta, Vikas , Tefferi, Ayalew , Vannucchi, Alessandro M. , Hillis, Christopher , Maze, Dawn , Prchal, Jaroslav F. , Olney, Harold J., Sirhan, Shireen , Vannucchi, Alessandro M , Szuber, Natasha , Gupta, Vikas , Leber, Brian F.

Mayo Clinic

American Journal of Hematology | September 24, 2022 | Volume: 97 | Issue: 12 | Pages: No page available

10.1002/ajh.26739 | PMID 36151067 Get It

The role of community‐level characteristics in comparing United States hospital performance by magnet designation: A propensity score matched study
Hamadi, Hanadi , Boamah, Sheila A. , Dorsey, Katherine, Zhao, Mei , Spaulding, Aaron , Menser, Terri , Hamadi, Hanadi Y , Boamah, Sheila A , Zhao, Mei , Spaulding, Aaron

Mayo Clinic

Journal of Advanced Nursing | September 24, 2022 | Volume: 79 | Issue: 5 | Pages: 1939-1948

10.1111/jan.15446 | PMID 36151700 Get It

Abstract Aims To assess the impact of community‐level characteristics on the role of magnet designation in relation to hospital value‐based purchasing quality scores, as health disparities associated with geographical location could confound hospitals' ability to meet outcome metrics. Design This cross‐sectional study was carried out between October 2021 and March 2022 using data from 2016 to 2021. Methods Propensity score analysis was used to match hospital and community‐level characteristics, implementing nearest neighbour matching to adjust for pre‐treatment differences between magnet and non‐magnet hospitals to account for multi‐level differences. Secondary data were obtained from all operational acute‐care facilities in the United States that participated in the Centers for Medicare and Medicaid Services' hospital value‐based purchasing (HVBP) program. Dependent variables were the four value‐based purchasing domains that comprise the Total Performance Score (TPS; Clinical Care, Person and Community Engagement, Safety, and Efficiency and Cost Reduction). Results Magnet hospitals had increased odds for better scores in the HVBP domains of Clinical Care and Person and Community Engagement, and decreased odds for having better Safety. However, no statistically significant difference was found for the Efficiency domain or the TPS. Conclusion Measuring performance equitably across organizations of various sizes serving diverse communities remains a key factor in ensuring distributive justice. Analysing the TPS components can identify complex influences of community‐level characteristics not evident at the composite level. More research is needed where community and nurse‐level factors may indirectly affect patient safety. Impact This study's findings on the role of community contexts can inform policymakers designing value‐based care programs and healthcare management administrators deliberating on magnet certification investments across diverse community settings. No patient or public contribution For this study of US hospitals' organizational performance, we did not engage members of the patient population nor the general public. However, the multi‐disciplinary research team does include diverse perspectives.
Horizontal Violence Toward Emergency Medicine Residents: Gender as a Risk Factor
Jacobson, Ashley , Colletti, James E., Jacobson, Ashley A, Raukar, Neha P.

Mayo Clinic

Western Journal of Emergency Medicine | September 23, 2022 | Volume: 23 | Issue: 5 | Pages: 633-636

10.5811/westjem.2022.6.55485 | PMID 36205679 Get It

Introduction: Horizontal violence (HV) is defined as “persistent exposure to interpersonal aggression and mistreatment from colleagues.” Our objective in this pilot, single-site study was to identify sources of HV toward emergency medicine (EM) residents, using the Negative Acts Questionnaire-Revised (NAQ-R). Methods: In this investigation we used a descriptive cross-sectional survey design to categorize HV. All voluntary participants were residents in an Accreditation Council for Graduate Medical Education- approved, three-year academic EM residency. Data were collected via electronic survey and occurred six months into an academic year. We collected demographic information and responses to the NAQ-R in 2020. Horizontal violence is subdivided into three categories: work-related; person-related; and physical intimidation. Emergency medicine residents answered questions as they related to their interactions with residents and support staff, which included nursing. Results: A total of 23 of 26 residents responded (89%). Participants were 56% women, 78% white, 11% Hispanic, and 89% heterosexual. Participant clinical year was 39% first-, 39% second-, and 22% third-year residents. Women reported a higher frequency of HV compared to men (1.3 vs 1.1, P =.01). By category, women indicated higher incidence of work-related violence from other residents (P = .05) and staff (P =.02). There was no difference in reported frequency of violence for interns compared to senior residents. Conclusion: Our pilot study demonstrated horizontal violence toward EM residents exists and is more prevalent in women.
Can Urinalysis and Past Medical History of Kidney Stones Predict Urine Antibiotic Resistance?
Mohseni, Michael , Craver, Emily C. , Sheele, Johnathan M. , Mohseni, Michael M , Heckman, Michael G.

Mayo Clinic

Western Journal of Emergency Medicine | September 23, 2022 | Volume: 23 | Issue: 5 | Pages: 613-617

10.5811/westjem.2022.4.54872 | PMID 36205684 Get It

Introduction: Urinary tract infections (UTI) are one of the most common infections encountered in the emergency department (ED) with an estimated 2-3 million annual visits. Commonly prescribed antibiotics for UTIs have shown growing rates of resistance. Previous studies lack direction on improving UTI treatment based on the labs available to the bedside clinician. Methods: We sought to determine if antibiotic resistance in UTIs was related to demographics, urinalysis, and history of renal failure or kidney stones. We conducted an analysis of 892 women ≥18 years of age discharged from the ED with a UTI diagnosis. We assessed predictors of nitrofurantoin resistance, cefazolin resistance, ciprofloxacin resistance, and trimethoprim-sulfamethoxazole resistance using unadjusted and multivariable logistic regression models. Results: Antibiotic resistance was 13.6% for nitrofurantoin, 11.9% for cefazolin, 12.8% for ciprofloxacin, and 17.1% for trimethoprim-sulfamethoxazole. In multivariable analysis, significant independent associations with an increased likelihood of resistance to nitrofurantoin were observed for less urine blood (OR [per 1 category increase of score] 0.81; P = 0.02); greater mucous (OR [per 1 category increase of score] 1.22; P = 0.02); less specific gravity urine (OR [per 1 category increase] 0.87; P = 0.04), and presence of any history of kidney stones (OR 3.24; P = 0.01). There were no significant predictors for cefazolin resistance (all P ≥0.06); age was the only significant predictor of ciprofloxacin resistance (OR per 10 year increase] 1.10, P = 0.05), and lower specific gravity urine was significantly associated with an increased risk of resistance to trimethoprim- sulfamethoxazole (OR [per 1 category increase] 0.88, P = 0.04). Conclusion: Women with any history of kidney stones may have bacteriuria resistant to nitrofurantoin, suggesting that providers might consider alternative antibiotic therapies in this scenario.
Paroxysmal sinus deceleration: an under-recognized show stopper
Padang, Ratnasari , Luis, Sushil A , Padang, Ratnasari , Luis, Sushil Allen

Mayo Clinic

European Heart Journal - Case Reports | September 23, 2022 | Volume: 6 | Issue: 10 | Pages: No page available

10.1093/ehjcr/ytac389 | PMID 36420418 Get It